Sionna Therapeutics (NASDAQ:SION) Trading Up 4.5% – Should You Buy?

Sionna Therapeutics, Inc. (NASDAQ:SION) shares were up 4.5% during trading on Tuesday . The company traded as high as $12.91 and last traded at $12.65. 11,004 shares changed hands during trading, a decline of 95% from the average daily volume of 231,585 shares. The stock had previously closed at $12.10.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the company. TD Cowen initiated coverage on Sionna Therapeutics in a research note on Tuesday, March 4th. They issued a “buy” rating on the stock. Stifel Nicolaus assumed coverage on shares of Sionna Therapeutics in a research note on Tuesday, March 4th. They issued a “buy” rating and a $32.00 price target on the stock. Finally, Guggenheim began coverage on shares of Sionna Therapeutics in a research report on Tuesday, March 4th. They issued a “buy” rating and a $45.00 price objective for the company.

Sionna Therapeutics Price Performance

Sionna Therapeutics (NASDAQ:SION) last announced its quarterly earnings results on Thursday, March 20th. The company reported ($3.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.68) by ($0.70).

About Sionna Therapeutics

We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.